Johnson & Johnson (JNJ)
J&J pauses rollout of heart device in the US to investigate stroke risk
Johnson & Johnson said on Wednesday that it has temporarily paused the rollout of its Varipulse heart device in the United States, citing an abundance of caution as the company investigates four reported stroke events.
Johnson & Johnson: A Potential Beneficiary Of A Great Rotation
Johnson & Johnson's stagnant price and bond-like behavior make it an income investment, but a market shift could boost its appeal in 2025. Value stocks, including JNJ, may gain favor as growth stocks' earnings slow and proposed policies boost earnings in other sectors. JNJ's 3.41% dividend yield and attractive forward PE ratio of 13.5 offer potential upside if value stocks regain market attention.
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
Johnson & Johnson (JNJ) reachead $146.18 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.
2 Dividend Kings to Rule Them All in 2025
If history is any teacher, the best thing you can do with your money is buy dividend stocks.
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note
The latest trading day saw Johnson & Johnson (JNJ) settling at $144.62, representing a +0.89% change from its previous close.
J&J Trading Near 52-Week Low: Should You Sell the Stock?
Those who own the stock may stay invested for some time as J&J looks optimistic about a better performance in 2025.
Johnson & Johnson Death Cross: Stock Stumbles Despite Pipeline Promise
Johnson & Johnson JNJ, the iconic healthcare giant known for its stable dividends and defensive appeal, has entered a bearish technical pattern: the Death Cross.
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723
Johnson & Johnson announces a global licensing deal with Kaken for the latter's eczema candidate, KP-723, to further strengthen its dermatology portfolio.
US FDA proposes standardized testing to detect asbestos in talc products
The U.S. Food and Drug Administration is proposing that cosmetic products containing talc should be tested using standardized methods to detect asbestos, a potential contaminant, according to documents posted on the federal register on Thursday.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Give Yourself the Gift That Will Keep On Giving in 2025 and Buy These 3 Top Dividend Stocks
Dividend-paying stocks are the gift that keeps on giving. They pay you a recurring stream of passive income that you can use to make new investments or cover some of your expenses.
